Oxandrolone

Androgen Receptor Binding and Myogenic Transcription#

Oxandrolone is a synthetic derivative of dihydrotestosterone (DHT) with two key structural modifications: an oxygen atom replacing the carbon at the 2-position of the A-ring (the "oxa" substitution), and a 17α-methyl group that lets it survive first-pass hepatic metabolism. It binds the androgen receptor (AR) with moderate affinity and drives classical AR-mediated transcription of myogenic genes — upregulating muscle protein synthesis, increasing intracellular amino-acid uptake, and improving nitrogen retention in skeletal muscle tissue. This is the core driver of the lean, strength-focused gains users pursue.

"Oxandrolone produces significant increases in muscle protein synthesis and has marked anticatabolic effects, with a favourable side-effect profile compared with other oral anabolic steroids." — Orr R, Singh MF, Drugs (2004)

Anticatabolic Signalling via Glucocorticoid Competition#

Beyond pure anabolic signalling, oxandrolone competes at the glucocorticoid receptor, blunting cortisol's catabolic signal in muscle tissue. This is why it preserves lean mass so effectively in a caloric deficit — the practical reason it became the default oral for cutting cycles and contest prep. The anticatabolic effect is also why burn and trauma literature features it so heavily: lean mass gained on oxandrolone is retained for months after discontinuation, rather than collapsing the moment the drug clears.

"Patients treated with oxandrolone demonstrated a significant increase in net lean mass during the treatment period, which was sustained for up to 6 months following discontinuation of therapy." — Demling RH, DeSanti L, Burns (2003)

No Aromatization, Minimal 5α-Reduction#

Because oxandrolone is DHT-derived, it does not aromatize to estrogen — no E2 conversion, no estrogenic water retention, no gyno risk, no AI required. The 2-oxa A-ring substitution also makes it a poor substrate for further 5α-reductase metabolism, meaning its androgenic signalling stays fairly site-limited and its androgenic rating (~24 vs testosterone's 100) is low relative to its anabolic rating (~322–630). Practical outcome: you get a dry, hard look with minimal bloat, and finasteride is useless for hair protection on this compound since oxandrolone is already a DHT analog — topical AR antagonists (RU58841, pyrilutamide) are the relevant tool.

SHBG Suppression and Free-Androgen Amplification#

One of oxandrolone's most underappreciated mechanisms: it has little affinity for sex hormone-binding globulin (SHBG) itself, but it lowers circulating SHBG, which raises the free (bioavailable) fraction of any co-administered androgen.

"Oxandrolone lacks significant aromatization to oestrogens and has little affinity for sex hormone-binding globulin, decreasing SHBG and increasing bioavailable androgen when co-administered with other androgens." — Grant B, Hyams E, Davies R, Minhas S, Jayasena CN, Ann NY Acad Sci (2024)

This is why a test + oxandrolone stack feels stronger than the raw dose math would suggest — your testosterone base becomes more bioavailable. It's also the mechanistic rationale for stacking with proviron, which works the same way.

Pharmacokinetic Advantages#

The combination of 17α-methylation and 2-oxa substitution gives oxandrolone exceptional oral bioavailability (~97%) and a cleaner metabolic profile than most c17-aa orals. Roughly 28% is excreted unchanged in urine — one reason its hepatotoxicity, while real, is milder than methyltest, anadrol, or superdrol. The ~9-hour half-life means twice-daily dosing (AM/PM or AM/pre-workout) gives steadier plasma levels than once-daily, and explains why experienced users split their daily total rather than front-loading it.

Collagen Synthesis and Connective Tissue#

Oxandrolone meaningfully upregulates collagen synthesis, which is why it appears in burn-recovery and wound-healing literature at clinical doses. For lifters, this translates to tendon and connective-tissue support — a reason some users run a low dose (20–30 mg/day) alongside injury rehab protocols rather than purely for physique purposes. It's a quieter benefit than strength or dryness, but it's real and it shows up in controlled trials.

Common (most users)#

• HDL crash / LDL rise — the defining side effect. Expect HDL to drop 30–50% within weeks at 50 mg/day. Mitigate with citrus bergamot 1,000 mg/day, 3–4 g EPA/DHA, consistent low-intensity cardio (150+ min/week), and keeping cycles to 6–8 weeks. If HDL is already marginal at baseline, fix it before starting.
• Suppressed natural testosterone — full LH/FSH shutdown within 1–2 weeks at 20+ mg/day. Run on a TRT-range test base (100–150 mg/week) rather than standalone; otherwise you spend the cycle hypogonadal and net flat total androgens.
• Mild appetite suppression — useful on a cut, annoying on a lean bulk. Front-load calories earlier in the day or pair doses with meals.
• Pumps (especially lower back, calves, forearms) — increased intracellular water and glycogen storage. Hydrate aggressively (3–4 L/day), keep sodium adequate, add taurine 3–5 g/day and potassium from food. Back off volume briefly if pumps become training-limiting.
• Mild acne / oily skin — androgenic baseline effect. Standard skincare (benzoyl peroxide, adapalene) handles it.
• Shedding in MPB-susceptible users — oxandrolone is DHT-derived, so finasteride is useless here (nothing to convert). The relevant tool is topical AR antagonists (RU58841, pyrilutamide) plus the standard minoxidil/ketoconazole base.
• Libido / erectile quality wobbles — usually tied to SHBG suppression shifting free androgen ratios rather than var itself. A proper test base and a daily low-dose tadalafil (2.5–5 mg) keep this sorted.

Uncommon (dose-dependent or individual)#

• Elevated ALT/AST — real, though milder than most 17α-alkylated orals. Burn-patient meta-analysis data put transaminase elevation at roughly 4× placebo rates:

"The incidence of elevation of transaminases in the oxandrolone group was significantly higher than in controls (19% vs 5%), confirming that routine liver monitoring remains warranted during therapy." — Lou et al., World J Emerg Surg (2025)

Run TUDCA 500 mg/day, skip alcohol, do not stack with another 17aa oral. Mid-cycle bloods at week 4. Back off or stop if ALT/AST pass ~3× ULN.

• Blood pressure creep — usually +5–15 mmHg systolic, driven by the lipid shift and mild fluid retention. Monitor weekly at home. If resting BP passes 140/90, add/tighten cardio, consider telmisartan 20–40 mg.
• SHBG crash — expected and partly desired (boosts free test), but extreme suppression can destabilize mood and libido. Shows up on bloods; back off dose if SHBG drops below ~10 nmol/L with symptoms.
• Kidney strain markers rising — creatinine will go up from muscle mass and creatine kinase flux; cystatin C is the better marker if you want to actually assess renal function on cycle.
• Mood flatness or irritability — more common in standalone runs (low total androgen) than in properly based cycles.

Rare but serious#

• Cholestatic liver injury — jaundice, dark urine, right-upper-quadrant pain, pale stools. Stop immediately and get a hepatic panel + bilirubin. Rare at standard doses and cycle lengths, more likely with oral stacking or 12+ week runs.
• Peliosis hepatis / hepatic adenomas — documented with long-term 17α-alkylated use. Another reason to respect the 6–8 week ceiling.
• Severe dyslipidemia → atherogenic remodeling — sustained HDL suppression across repeated cycles is the real cardiovascular risk with var, not acute events. Cycle discipline and off-cycle lipid recovery matter more than any single mitigation.
• Cardiac hypertrophy / adverse remodeling — pooled with chronic AAS use generally, dose- and duration-dependent. Keep cycles discrete, not continuous.
• Permanent virilization in women — voice deepening and clitoromegaly do not reverse once established. See below.

Hard contraindications#

• Untreated hypertension or dyslipidemia — fix the baseline before starting, not during.
• Active liver disease (hepatitis, cholestasis, elevated baseline LFTs) — do not run any 17aa oral.
• Concurrent second 17α-alkylated oral (dbol, anadrol, superdrol, winstrol, turinabol) — compounded hepatotoxicity and lipid damage, no clinical upside that can't be achieved with an injectable pairing.
• Prostate cancer or breast cancer (current or history) — androgen-driven malignancy.
• Pregnancy or possible pregnancy — teratogenic; virilizes female fetuses.
• Heavy alcohol use during the cycle — stacks hepatic load.

Women and PCT#

Virilization is the rate-limiter for female users. Cap at 10 mg/day, 6–8 weeks max, split AM/PM. Stop immediately at the first sign of voice deepening, clitoral hypertrophy, or significant hirsutism — these effects can be permanent if you train through them. Acne and shedding reverse; voice and clitoral changes often do not. Advanced competitors occasionally push 15–20 mg, but risk rises steeply and the cost of getting it wrong is lifelong. Bloods at baseline and mid-cycle; no test base is needed or wanted for women.

PCT for men: required unless you're running a permanent TRT base. Standard protocol after an 8-week run with a mild test dose:

Start PCT ~3 days after last test ester clears (depends on ester used). Mid-PCT bloods at week 3 to confirm LH/FSH/test are recovering. Oxandrolone's clean non-aromatizing profile means recovery is generally straightforward provided you weren't standalone-suppressed for months on end.